Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics Inc. (NASDAQ: CTNM) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel, oral small molecule therapies targeting diseases with high unmet medical needs. With a strong emphasis on innovation and precision medicine, the company focuses on addressing complex conditions in the fields of neuroinflammation and immunology (NI&I), where effective treatment options remain limited.
Core Focus and Drug Development Pipeline
Contineum Therapeutics' internally-discovered drug candidates are designed to leverage advanced molecular mechanisms to provide targeted therapeutic benefits. The company’s pipeline includes two key candidates:
- PIPE-791: A novel, brain-penetrant, small molecule inhibitor of the lysophosphatidic acid receptor 1 (LPA1R), currently in development for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a progressive and life-threatening lung disease characterized by scarring of lung tissue, and PIPE-791 aims to address the underlying pathology by modulating the LPA1R pathway.
- PIPE-307: A selective small molecule inhibitor of the muscarinic type 1 receptor (M1R), being developed to treat depression and relapsing-remitting multiple sclerosis (RRMS). By targeting M1R, PIPE-307 offers a potential therapeutic approach that may improve neurological and inflammatory outcomes in these conditions.
Innovative Approach to Drug Development
Contineum Therapeutics differentiates itself through its focus on orally administered small molecules, which provide significant advantages in terms of patient compliance and ease of use compared to injectable or biologic therapies. These small molecules are designed to be highly selective, reducing off-target effects and enhancing safety profiles. The company’s emphasis on brain-penetrant compounds further underscores its commitment to addressing challenging neurological and systemic conditions with precision.
Market Position and Industry Context
Operating within the competitive biopharmaceutical industry, Contineum Therapeutics positions itself as a pioneer in the development of therapies for underserved medical conditions. The company’s focus on IPF, depression, and RRMS places it in direct competition with both established pharmaceutical companies and other clinical-stage biotechs pursuing similar indications. However, its unique approach to leveraging small molecule inhibitors, combined with its focus on oral administration, provides a distinct competitive edge.
Challenges and Opportunities
As a clinical-stage company, Contineum Therapeutics faces the inherent risks associated with drug development, including the need to demonstrate safety and efficacy in rigorous clinical trials and navigate the regulatory approval process. Additionally, securing funding for ongoing research and development is critical to advancing its pipeline. Nevertheless, the company’s focus on high unmet medical needs and its innovative therapeutic strategies position it as a potentially transformative player in the biopharmaceutical landscape.
Commitment to Addressing Unmet Needs
Through its robust research and development efforts, Contineum Therapeutics aims to provide patients with effective and accessible treatment options for challenging diseases. By targeting the underlying mechanisms of disease pathology, the company seeks to improve quality of life for patients and address significant gaps in existing treatment paradigms.
Contineum Therapeutics (NASDAQ: CTNM) has completed enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis (RRMS). The trial, designed to assess safety and efficacy, will evaluate multiple clinical and imaging endpoints sensitive to remyelination changes in RRMS patients.
PIPE-307, being developed under a global license agreement with Janssen Pharmaceutica NV, is positioned as a potentially first-in-class M1 receptor antagonist. The Phase 2 study is randomized, double-blind, placebo-controlled, and multi-center. The last patient is expected to complete the trial in Q3 2025, with enrollment completion achieved ahead of schedule in December 2024.
Contineum Therapeutics (NASDAQ: CTNM) has initiated patient dosing in its Phase 1b PET trial for PIPE-791, a novel brain penetrant small molecule antagonist targeting the LPA1 receptor. The open-label, single-center trial aims to evaluate receptor occupancy in the brain and lungs of multiple patient cohorts, including healthy volunteers, idiopathic pulmonary fibrosis (IPF), and progressive multiple sclerosis (PrMS) patients.
The study will measure the correlation between pharmacokinetics and receptor occupancy using PET imaging. The company expects to release topline data in the second quarter of 2025. The trial is registered under NCT06683612.
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company's management will engage in a fireside chat on December 4, 2024, at 11:15 a.m. ET in Miami. The event will be accessible via audio webcast through Contineum's website's Investors section, with a replay option available.
Contineum Therapeutics (NASDAQ: CTNM) received FDA authorization for its IND application for PIPE-791, targeting chronic pain treatment. The company plans to commence a Phase 1b study in Q1 2025 for osteoarthritis and low back pain treatment. The study will be randomized, double-blind, placebo-controlled, involving approximately 40 patients across five sites with a 28-day treatment duration. Topline data is expected in early 2026. PIPE-791 is a novel brain penetrant small molecule antagonist of LPA1R, targeting neuropathic pain components. The company's cash position of $213.9 million is expected to fund operations through 2027.
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in two major investor conferences in November 2024.
The company will attend the Stifel 2024 Healthcare Conference in New York on November 18, where CEO Carmine Stengone will present at 4:10 p.m. ET. Additionally, management will participate in one-on-one meetings at the Jefferies 2024 London Healthcare Conference on November 21. The Stifel presentation will be available via webcast on Contineum's website with replay access.
Contineum Therapeutics (Nasdaq: CTNM) reported its Q3 2024 financial results and recent business highlights. The company continued enrolling patients in its Phase 2 VISTA trial of PIPE-307 for RRMS, achieving two-thirds enrollment. It expects full enrollment by H1 2025. Contineum submitted a CTA to the MHRA for a Phase 1b trial of PIPE-791, targeting healthy volunteers and patients with progressive multiple sclerosis and IPF, aiming to start in December 2024. Janssen Pharmaceutica remains on track to start a Phase 2 trial of PIPE-307 in depression. The company holds $214 million in cash, expected to support operations through 2027. Q3 R&D expenses rose to $9.7 million from $6.5 million YoY, driven by increased costs for ongoing trials and toxicology studies. General and administrative expenses also increased to $3.3 million from $1.6 million YoY, mainly due to higher stock-based compensation and consulting costs.
Contineum Therapeutics (Nasdaq: CTNM), a clinical stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The company, which focuses on developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications, will be represented by its President and CEO, Carmine Stengone.
The conferences are:
- Morgan Stanley 22nd Annual Global Healthcare Conference (September 4-6, 2024, New York) - Presentation on September 4 at 7:00 am ET
- H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024, New York) - Presentation on September 10 at 2:30 pm ET
Both presentations will be available via webcast on Contineum's website, with replays accessible after the events conclude.
Contineum Therapeutics (Nasdaq: CTNM) reported Q2 2024 financial results and recent business highlights. Key points include:
- Strong cash position of $219 million at Q2 end
- Appointed Troy Ignelzi and Sarah Boyce to Board of Directors
- Strengthened management team with John Healy and Kristina Haeckl
- Enrollment on track for PIPE-307 Phase 2 VISTA trial in RRMS
- Published preclinical and clinical results on PIPE-307 and PIPE-791
- Completed IPO with net proceeds of $107.9 million
Financial results:
- R&D expenses: $7.9 million (Q2 2024) vs $9.5 million (Q2 2023)
- G&A expenses: $3.0 million (Q2 2024) vs $1.6 million (Q2 2023)
Contineum Therapeutics (Nasdaq: CTNM) has announced the publication of encouraging preclinical data on PIPE-307, a potentially first-in-class M1 receptor antagonist for relapse-remitting multiple sclerosis (RRMS), in the Proceedings of the National Academy of Science. The data suggest that PIPE-307 is a novel, selective inhibitor of the muscarinic type 1 M1 receptor, which may promote remyelination in multiple sclerosis.
The company has completed two Phase 1 trials in healthy volunteers and initiated a Phase 2 multi-center, randomized, double-blind, placebo-controlled proof-of-concept clinical trial (VISTA) in RRMS patients. This trial will assess efficacy and safety, measuring multiple clinical and imaging endpoints sensitive to changes in remyelination. PIPE-307 is being developed under a global license and development agreement with Janssen Pharmaceutica NV.
Contineum Therapeutics (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, announced its participation in the 45th Annual Goldman Sachs Healthcare Conference, from June 10-13, 2024, in Miami.
Carmine Stengone, President and CEO, will engage in a fireside chat on June 10 at 8:40 am ET, with the event webcast live on Contineum’s website. The company will also hold one-on-one meetings with investors throughout the conference.
FAQ
What is the current stock price of Contineum Therapeutics (CTNM)?
What is the market cap of Contineum Therapeutics (CTNM)?
What does Contineum Therapeutics specialize in?
What are the key drug candidates in Contineum Therapeutics' pipeline?
What makes Contineum Therapeutics' approach unique?
What challenges does Contineum Therapeutics face?
Who are Contineum Therapeutics' competitors?
What is PIPE-791 and what does it treat?
What is PIPE-307 and what does it treat?
What advantages do small molecule therapies offer?
What is Contineum Therapeutics' market focus?
